Music therapy reduces distress and improves well-being in advanced dementia by meeting unmet needs, enhancing ...
A clinical trial has shown promising results in treating brain tumours in children using an immune-cell therapy known as ...
Nipocalimab is a fully human monoclonal antibody that blocks FcRn and decreases levels of circulating IgG antibodies.
Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation ...
The US Food and Drug Administration (FDA) has awarded the second breakthrough therapy designation (BTD) to Johnson & ...
The US FDA has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating acute leukaemia with KMT2A translocation.
As psychedelic medicine inches closer to mainstream acceptance, researchers have tackled a crucial question: How many ...
Research from the College of Medicine provides promising insights into delaying the progression of Alzheimer’s disease for several years after the initial diagnosis. A recent study by researchers at C ...
Third quarter global net product sales of $90.3 million; 2024 guidance increased to $330 - 335 million Volixibat granted ...
A revolutionary breakthrough in cataract treatment is on the horizon, with the emergence of C-KAD, a new eye drop therapy.
Johnson & Johnson (J&J) has announced that its anti-FcRn antibody nipocalimab has become the first investigational therapy to ...
UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver disease associated with ...